Evidence map›Paper›PMID 38257322›Full record

ArticleMolecules (Basel, Switzerland)2024

Design, Synthesis, and Antitumor Activity Evaluation of Artemisinin Bivalent Ligands.

Hui Zhong, Qi Jiang, Cong Wu, Huanghe Yu, Bin Li, Xudong Zhou, Ronggeng Fu, Wei Wang, Wenbing Sheng

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. The Therapeutic Potential of Dihydroartemisinin in Cancer Treatment.International journal of molecular sciences · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Hui ZhongSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Qi JiangSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Cong WuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Huanghe YuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Bin LiSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Xudong ZhouSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0001-7445-5428
Ronggeng FuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Wei WangSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0003-0876-2205
Wenbing ShengSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0000-0002-9780-0033
Hunan University of Traditional Chinese Medicine · CN

Funding

Hunan Education Department Scientific Research Project 19B433Hunan Education Department Scientific Research Project 21A0239Natural Science Foundation of Hunan Province 2021JJ30502
6 · The paper itself

Abstract

Five artemisinin bivalent ligands molecules

Indexed as

ArtemisininsCell Line, TumorHumansLigandsMolecular Docking SimulationartemisininArtemisininsLigandsantitumor activityantitumor target proteinartemisininbivalent ligandsmulti-target molecular docking

Identifiers

PMID38257322
PMCPMC10818997
OpenAlexW4390879571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.